uracil has been researched along with Neoplasm Metastasis in 114 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile." | 9.30 | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. ( Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T, 2019) |
| " We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin." | 9.20 | Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ( Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T, 2015) |
| "This Phase II trial investigated the combination paclitaxel (P) and uracil-tegafur (UFT) in patients with metastatic breast cancer (MBC)." | 9.15 | Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial. ( Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C, 2011) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 9.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 9.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 9.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 9.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 9.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer." | 9.09 | Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. ( Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP, 1999) |
| "This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) for advanced metastatic breast cancer." | 9.09 | Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer. ( Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S, 1999) |
| "Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers." | 9.09 | UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. ( Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 9.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscularly in combination with UFT given orally and leucovorin given orally." | 9.09 | Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. ( Casado, A; Diaz-Rubio, E; Garcia-Carbonero, I; Garcia-Saenz, JA; Macias, JA; Manrique, I; Martín, M; Oruezabal, M, 2000) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 9.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 9.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking." | 9.05 | Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? ( Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q, 2020) |
| "Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)." | 9.01 | A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. ( Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 8.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 7.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 7.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients with refractory metastatic colorectal cancer." | 7.85 | Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. ( Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T, 2017) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 7.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 7.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine." | 6.94 | First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. ( Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020) |
| "Eniluracil/5-FU/Lv might enable these patients to continue with oral 5-FU rather than switching to the generally less well tolerated intravenous microtubule-interfering agents." | 6.79 | Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed. ( Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T, 2014) |
| "Ninety-one patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 6.75 | A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. ( Booser, DJ; Heim, W; Hortobagyi, GN; Hutchins, L; Kirshner, J; Mason, B; Rivera, E, 2010) |
| "Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 6.75 | A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. ( Gore, I; Hermann, R; Hortobagyi, GN; Ibrahim, NK; Karwal, M; Murray, JL; Watkins, SP; Young, RR, 2010) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 6.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 6.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| " Inactivation of DPD using eniluracil is advantageous in that it renders 5-FU orally bioavailable with more predictable pharmacokinetics and blocks one of the major potential mechanisms of 5-FU chemoresistance." | 6.71 | Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ( Diasio, RB; Heslin, MJ; Lucas, VS; Owens, J; Shao, L; Weiss, H; Yan, J, 2003) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 6.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| "Breast cancer is the most common cause of cancer-related death among women, and prognosis is especially poor for patients with triple-negative breast cancer (TNBC); therefore, there is an urgent need for new effective therapies." | 5.62 | A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. ( Chen, M; Jiang, D; Liao, WZ; Peng, HJ; Xu, LQ; Yao, LJ; Zhou, LJ; Zou, WH, 2021) |
| "TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer." | 5.34 | TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020) |
| "A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile." | 5.30 | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. ( Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T, 2019) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 5.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| "Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC)." | 5.24 | Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. ( Antonuzzo, L; Aprile, G; Baretti, M; Battaglin, F; Berenato, R; Beretta, G; Bozzarelli, S; Cinieri, S; Cremolini, C; de Braud, F; Falcone, A; Formica, V; Ghidini, M; Lonardi, S; Loupakis, F; Marmorino, F; Mennitto, A; Miceli, R; Morano, F; Mosconi, S; Petrelli, F; Pietrantonio, F; Rimassa, L; Rossini, D; Spada, D; Tamburini, E, 2017) |
| "Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer." | 5.20 | Randomized trial of TAS-102 for refractory metastatic colorectal cancer. ( Benedetti, F; Boucher, E; Cleary, JM; Falcone, A; Garcia-Carbonero, R; Hochster, H; Ito, M; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Mizuguchi, H; Mizunuma, N; Ohtsu, A; Peeters, M; Prenen, H; Shimada, Y; Sobrero, A; Tabernero, J; Tran, B; Van Cutsem, E; Yamazaki, K; Yoshino, T; Zaniboni, A, 2015) |
| " We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin." | 5.20 | Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ( Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T, 2015) |
| "This Phase II trial investigated the combination paclitaxel (P) and uracil-tegafur (UFT) in patients with metastatic breast cancer (MBC)." | 5.15 | Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial. ( Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C, 2011) |
| "Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as treatment for metastatic colorectal cancer (mCRC)." | 5.13 | A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. ( Abbruzzese, JL; Anthony, L; Hoff, PM; Kopetz, S; Langleben, A; Lassere, Y; Rinaldi, D; Thomas, MB; Wolff, RA, 2008) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 5.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 5.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 5.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "A phase II study was performed to evaluate the clinical efficacy and toxicity of oxaliplatin combined with uracil and tegafur (UFT) in patients with advanced colorectal cancer previously treated with a fluoropyrimidine-based regimen." | 5.10 | Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. ( Chun, H; Im, YH; Jung, CW; Kang, WK; Kim, JH; Kim, K; Kim, WS; Lee, HR; Lee, JY; Lee, MH; Lee, NS; Lee, WY; Nam, E; Oh, SY; Park, CH; Park, JO; Park, K; Park, SH; Song, SY, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 5.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer." | 5.09 | Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. ( Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP, 1999) |
| "This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) for advanced metastatic breast cancer." | 5.09 | Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer. ( Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S, 1999) |
| "Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers." | 5.09 | UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. ( Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 5.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscularly in combination with UFT given orally and leucovorin given orally." | 5.09 | Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. ( Casado, A; Diaz-Rubio, E; Garcia-Carbonero, I; Garcia-Saenz, JA; Macias, JA; Manrique, I; Martín, M; Oruezabal, M, 2000) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 5.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 5.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "The activity and toxicity of UFT (Tegafur and Uracil) in a 4:1 molar concentration, plus leucovorin (LV), were evaluated in the treatment of 45 patients with advanced, bidimensionally measurable metastatic colorectal carcinoma." | 5.08 | Phase II study of UFT plus leucovorin in colorectal cancer. ( Pazdur, R, 1997) |
| "Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking." | 5.05 | Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? ( Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q, 2020) |
| "Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)." | 5.01 | A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. ( Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 4.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| " Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years." | 4.82 | New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 3.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 3.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD." | 3.85 | Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. ( Barzi, A; Berger, MD; Borelli, B; Cao, S; Dadduzio, V; Gopez, R; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Pietrantonio, F; Salvatore, L; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W, 2017) |
| "Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients with refractory metastatic colorectal cancer." | 3.85 | Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. ( Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T, 2017) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 3.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 3.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| " We tested a "doublet" combination metronomic chemotherapy treatment using two oral drugs, UFT, a 5-fluorouracil (5-FU) prodrug administered by gavage, and cyclophosphamide, for efficacy and toxicity in a new mouse model of advanced, terminal, metastatic human breast cancer." | 3.73 | Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. ( Francia, G; Kerbel, RS; Lee, CR; Man, S; Munoz, R; Shaked, Y; Wong, J, 2006) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine." | 2.94 | First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. ( Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020) |
| "Metastatic gastric cancer patients with stable disease or a better response after the completion of first-line chemotherapy were randomized to oral UFT (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity or to observation (OBS)." | 2.84 | Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. ( Chen, Z; Guo, W; Huang, M; Li, J; Li, W; Liu, X; Qiu, L; Wang, H; Zhang, W; Zhao, X; Zhu, X, 2017) |
| "Irinotecan was supplied at doses of 40, 50, 60, and 70 mg/m(2) by using a standard 3+3 design." | 2.82 | Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study. ( Chang, PM; Chen, SC; Yang, MH, 2016) |
| "Eniluracil/5-FU/Lv might enable these patients to continue with oral 5-FU rather than switching to the generally less well tolerated intravenous microtubule-interfering agents." | 2.79 | Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed. ( Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T, 2014) |
| "Ninety-one patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 2.75 | A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. ( Booser, DJ; Heim, W; Hortobagyi, GN; Hutchins, L; Kirshner, J; Mason, B; Rivera, E, 2010) |
| "Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 2.75 | A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. ( Gore, I; Hermann, R; Hortobagyi, GN; Ibrahim, NK; Karwal, M; Murray, JL; Watkins, SP; Young, RR, 2010) |
| "Oxaliplatin is an effective drug in gastric cancer, but, as previously reported, its feasibility in combination with capecitabine is hampered due to combined hand-foot-based toxicity." | 2.75 | Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. ( Drenth, AF; Hospers, GA; Mulder, NH; Plukker, JT; Siemerink, EJ, 2010) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 2.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| " In total, 79 courses were administered with a median of 3 (range 1-6)." | 2.72 | UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors. ( Abad, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gallego, J; Gómez, A; López, E; Manzano, JL; Sastre, J, 2006) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 2.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| " Inactivation of DPD using eniluracil is advantageous in that it renders 5-FU orally bioavailable with more predictable pharmacokinetics and blocks one of the major potential mechanisms of 5-FU chemoresistance." | 2.71 | Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ( Diasio, RB; Heslin, MJ; Lucas, VS; Owens, J; Shao, L; Weiss, H; Yan, J, 2003) |
| "In addition, remote metastases tended to be suppressed for both colon and rectal cancer in Group A (p=0." | 2.71 | Pre- and post-operative adjuvant chemotherapy in colorectal cancer. ( Isomoto, H; Kakegawa, T; Mori, M; Nakagoe, T; Ogawa, M; Sugimachi, K; Takano, S; Tomita, M; Yamada, K, 2003) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 2.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| "A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed." | 2.70 | Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. ( Ho, CM; Ho, WK; Lam, P; Wei, WI; Yuen, AP, 2001) |
| "The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic breast carcinoma." | 2.70 | Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. ( Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V, 2002) |
| "Molecular mechanisms of colorectal cancer are at the forefront of research." | 2.53 | Current and advancing treatments for metastatic colorectal cancer. ( Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J, 2016) |
| "Treatment of 'metastasis', in retrospect, usually involves minimal residual disease and therapy naïve tumors." | 2.44 | On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. ( Kerbel, RS; Man, S; Munoz, R, 2007) |
| "A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago." | 2.43 | Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005) |
| "Metastatic colorectal cancer remains a public-health issue on a global scale." | 2.43 | Metastatic colorectal cancer. ( Cavalli, F; Saletti, P, 2006) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "Breast cancer is the most common cause of cancer-related death among women, and prognosis is especially poor for patients with triple-negative breast cancer (TNBC); therefore, there is an urgent need for new effective therapies." | 1.62 | A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. ( Chen, M; Jiang, D; Liao, WZ; Peng, HJ; Xu, LQ; Yao, LJ; Zhou, LJ; Zou, WH, 2021) |
| "Here, we report a case of metastatic rectal cancer showing a complete response (CR) to cycle 4 in FOLFIRI regimen, while maintaining a CR status for over 11 months and good QOL, as a result of chemotherapy with 4 cycles of FOLFIRI followed by UFT." | 1.34 | [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT]. ( Baba, K; Matsuda, M; Tashima, R; Yamashita, Y; Yokoyama, S, 2007) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "However, the sensitivity to the micrometastases was high." | 1.31 | Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model. ( Fujioka, A; Fukushima, M; Nakano, K; Okabe, H; Saito, H; Sato, K; Takechi, T; Takeda, S; Uchida, J; Unemi, N, 2000) |
| "The extent of lymphatic metastasis is the most important factor in the prognosis for non-small cell lung cancer (NSCLC)." | 1.31 | Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. ( Fujino, H; Ishikura, H; Kinoshita, H; Kondo, K; Miyoshi, T; Monden, Y; Takahashi, Y, 2001) |
| "Pulmonary metastases were not inhibited by the treatment with AHCC plus UFT, whereas metastases to axillary lymph nodes (LN) were obviously inhibited." | 1.30 | Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. ( Hosokawa, M; Kobayashi, M; Kuramitsu, Y; Li, YQ; Matsushita, K; Obara, M; Ohiro, Y, 1998) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 1.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| "We recently established a spontaneous metastasis model of MKL-4 human breast cancer cells transplanted into nude mice." | 1.29 | [Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice]. ( Kurebayashi, J; Sonoo, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (7.89) | 18.7374 |
| 1990's | 11 (9.65) | 18.2507 |
| 2000's | 53 (46.49) | 29.6817 |
| 2010's | 33 (28.95) | 24.3611 |
| 2020's | 8 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, LQ | 1 |
| Yao, LJ | 1 |
| Jiang, D | 1 |
| Zhou, LJ | 1 |
| Chen, M | 1 |
| Liao, WZ | 1 |
| Zou, WH | 1 |
| Peng, HJ | 1 |
| Grothey, A | 1 |
| Marshall, JL | 1 |
| Bekaii-Saab, T | 2 |
| Zhang, Q | 1 |
| Wang, Q | 1 |
| Wang, X | 1 |
| Li, J | 2 |
| Shen, L | 1 |
| Peng, Z | 1 |
| Kotani, D | 1 |
| Kuboki, Y | 1 |
| Horasawa, S | 1 |
| Kaneko, A | 1 |
| Nakamura, Y | 1 |
| Kawazoe, A | 1 |
| Bando, H | 1 |
| Taniguchi, H | 2 |
| Shitara, K | 1 |
| Kojima, T | 2 |
| Tsuji, A | 2 |
| Yoshino, T | 4 |
| André, T | 1 |
| Saunders, M | 1 |
| Kanehisa, A | 1 |
| Gandossi, E | 1 |
| Fougeray, R | 1 |
| Amellal, NC | 1 |
| Falcone, A | 4 |
| Pfeiffer, P | 3 |
| Yilmaz, M | 1 |
| Möller, S | 1 |
| Zitnjak, D | 1 |
| Krogh, M | 1 |
| Petersen, LN | 1 |
| Poulsen, LØ | 1 |
| Winther, SB | 1 |
| Thomsen, KG | 1 |
| Qvortrup, C | 1 |
| Iveson, T | 1 |
| Carter, AM | 1 |
| Shiu, KK | 1 |
| Spooner, C | 1 |
| Stevens, D | 1 |
| Mullamitha, S | 1 |
| Siebenhüner, A | 1 |
| De Dosso, S | 1 |
| Meisel, A | 1 |
| Wagner, AD | 1 |
| Borner, M | 3 |
| Walter, T | 1 |
| Hawkins, NS | 1 |
| Pollock, RF | 1 |
| Colaone, F | 1 |
| Shergill, S | 1 |
| Ross, PJ | 1 |
| Suenaga, M | 1 |
| Schirripa, M | 2 |
| Cao, S | 1 |
| Zhang, W | 2 |
| Yang, D | 1 |
| Dadduzio, V | 1 |
| Salvatore, L | 2 |
| Borelli, B | 1 |
| Pietrantonio, F | 2 |
| Ning, Y | 1 |
| Okazaki, S | 1 |
| Berger, MD | 1 |
| Miyamoto, Y | 2 |
| Gopez, R | 1 |
| Barzi, A | 1 |
| Yamaguchi, T | 1 |
| Loupakis, F | 3 |
| Lenz, HJ | 3 |
| Arnold, D | 1 |
| Prager, GW | 1 |
| Quintela, A | 1 |
| Stein, A | 1 |
| Moreno Vera, S | 1 |
| Mounedji, N | 1 |
| Taieb, J | 1 |
| Kawahara, H | 1 |
| Mouri, T | 1 |
| Ishida, K | 1 |
| Matsumoto, N | 1 |
| Akiba, T | 1 |
| Yanaga, K | 1 |
| Martinez-Perez, J | 1 |
| Riesco-Martinez, MC | 1 |
| Garcia-Carbonero, R | 2 |
| Kimura, M | 1 |
| Usami, E | 1 |
| Teramachi, H | 1 |
| Yoshimura, T | 1 |
| Fernandez Montes, A | 1 |
| Vazquez Rivera, F | 1 |
| Martinez Lago, N | 1 |
| Covela Rúa, M | 1 |
| Cousillas Castiñeiras, A | 1 |
| Gonzalez Villarroel, P | 1 |
| de la Cámara Gómez, J | 1 |
| Méndez Méndez, JC | 1 |
| Salgado Fernández, M | 1 |
| Candamio Folgar, S | 1 |
| Reboredo López, M | 1 |
| Carmona Campos, M | 1 |
| Gallardo Martín, E | 1 |
| Jorge Fernández, M | 1 |
| Pellón Augusto, ML | 1 |
| París Bouzas, L | 1 |
| García Gómez, J | 1 |
| Sonbol, MB | 1 |
| Benkhadra, R | 1 |
| Wang, Z | 1 |
| Firwana, B | 1 |
| Walden, DJ | 1 |
| Mody, K | 1 |
| Hubbard, JM | 1 |
| Murad, MH | 1 |
| Ahn, DH | 1 |
| Matsuda, A | 1 |
| Yamada, T | 1 |
| Matsumoto, S | 1 |
| Sakurazawa, N | 1 |
| Kawano, Y | 1 |
| Shinozuka, E | 1 |
| Sekiguchi, K | 1 |
| Suzuki, H | 1 |
| Yoshida, H | 1 |
| Rivera, E | 3 |
| Chang, JC | 1 |
| Semiglazov, V | 1 |
| Burdaeva, O | 1 |
| Kirby, MG | 1 |
| Spector, T | 1 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| Guchelaar, HJ | 1 |
| van Kuilenburg, AB | 1 |
| Maring, JG | 1 |
| Gelderblom, H | 1 |
| Mayer, RJ | 1 |
| Van Cutsem, E | 2 |
| Mizunuma, N | 2 |
| Yamazaki, K | 4 |
| Shimada, Y | 1 |
| Tabernero, J | 2 |
| Komatsu, Y | 2 |
| Sobrero, A | 1 |
| Boucher, E | 1 |
| Peeters, M | 1 |
| Tran, B | 1 |
| Zaniboni, A | 1 |
| Hochster, H | 2 |
| Cleary, JM | 1 |
| Prenen, H | 1 |
| Benedetti, F | 1 |
| Mizuguchi, H | 1 |
| Makris, L | 1 |
| Ito, M | 1 |
| Ohtsu, A | 3 |
| Cleghorn, S | 1 |
| Doi, T | 1 |
| Fuse, N | 1 |
| Boku, N | 1 |
| Koizumi, W | 1 |
| Shimada, K | 1 |
| Takinishi, Y | 1 |
| Yoshimatsu, K | 1 |
| Yokomizo, H | 1 |
| Nakayama, M | 1 |
| Okayama, S | 1 |
| Satake, M | 1 |
| Sakuma, A | 1 |
| Yano, Y | 1 |
| Matsumoto, A | 1 |
| Fujimoto, T | 1 |
| Usui, T | 1 |
| Yamaguchi, K | 2 |
| Shiozawa, S | 1 |
| Shimakawa, T | 1 |
| Katsube, T | 1 |
| Naritaka, Y | 1 |
| Rossini, D | 2 |
| Moretto, R | 1 |
| Cremolini, C | 2 |
| Antoniotti, C | 1 |
| Marmorino, F | 2 |
| Masi, G | 1 |
| Sanz-Garcia, E | 1 |
| Grasselli, J | 1 |
| Argiles, G | 1 |
| Elez, ME | 1 |
| Baba, H | 2 |
| Goldberg, R | 1 |
| Chen, SC | 1 |
| Chang, PM | 1 |
| Yang, MH | 1 |
| Sueda, T | 1 |
| Sakai, D | 1 |
| Kudo, T | 1 |
| Sugiura, T | 1 |
| Takahashi, H | 1 |
| Haraguchi, N | 1 |
| Nishimura, J | 1 |
| Hata, T | 1 |
| Hayashi, T | 1 |
| Mizushima, T | 1 |
| Doki, Y | 1 |
| Mori, M | 2 |
| Satoh, T | 1 |
| Masuishi, T | 1 |
| Hamauchi, S | 1 |
| Komori, A | 1 |
| Kito, Y | 1 |
| Narita, Y | 1 |
| Tsushima, T | 1 |
| Ishihara, M | 1 |
| Todaka, A | 1 |
| Tanaka, T | 1 |
| Yokota, T | 1 |
| Kadowaki, S | 1 |
| Machida, N | 1 |
| Ura, T | 1 |
| Fukutomi, A | 1 |
| Ando, M | 1 |
| Onozawa, Y | 1 |
| Tajika, M | 1 |
| Yasui, H | 1 |
| Muro, K | 2 |
| Mori, K | 1 |
| Miceli, R | 1 |
| Rimassa, L | 1 |
| Lonardi, S | 1 |
| Aprile, G | 1 |
| Mennitto, A | 1 |
| Bozzarelli, S | 1 |
| Antonuzzo, L | 1 |
| Tamburini, E | 1 |
| Morano, F | 1 |
| Battaglin, F | 1 |
| Baretti, M | 1 |
| Berenato, R | 1 |
| Formica, V | 1 |
| Mosconi, S | 1 |
| Petrelli, F | 1 |
| Ghidini, M | 1 |
| Spada, D | 1 |
| Cinieri, S | 1 |
| Beretta, G | 1 |
| de Braud, F | 1 |
| Li, W | 1 |
| Zhao, X | 2 |
| Wang, H | 1 |
| Liu, X | 1 |
| Huang, M | 1 |
| Qiu, L | 1 |
| Chen, Z | 1 |
| Guo, W | 1 |
| Zhu, X | 1 |
| Lee, JJ | 1 |
| Chu, E | 1 |
| Hoff, PM | 2 |
| Kopetz, S | 1 |
| Thomas, MB | 1 |
| Langleben, A | 1 |
| Rinaldi, D | 1 |
| Anthony, L | 1 |
| Wolff, RA | 1 |
| Lassere, Y | 2 |
| Abbruzzese, JL | 3 |
| Niki, T | 1 |
| Yamamoto, Y | 1 |
| Tsuda, M | 1 |
| Horita, K | 1 |
| Hirohata, S | 1 |
| Nishisaki, H | 1 |
| Tsuchiya, T | 1 |
| Hiramatsu, K | 1 |
| Tanaka, H | 1 |
| Machiki, Y | 1 |
| Sakuragawa, T | 1 |
| Otsuji, H | 1 |
| Hara, T | 1 |
| Kimura, A | 1 |
| Yoshida, K | 1 |
| Hosoya, J | 1 |
| Kato, K | 2 |
| Hortobagyi, GN | 3 |
| Heim, W | 1 |
| Hutchins, L | 1 |
| Mason, B | 1 |
| Booser, DJ | 2 |
| Kirshner, J | 1 |
| Young, RR | 1 |
| Karwal, M | 1 |
| Ibrahim, NK | 1 |
| Hermann, R | 1 |
| Murray, JL | 1 |
| Watkins, SP | 1 |
| Gore, I | 1 |
| Siemerink, EJ | 1 |
| Drenth, AF | 1 |
| Mulder, NH | 1 |
| Plukker, JT | 1 |
| Hospers, GA | 1 |
| Li, CP | 1 |
| Chen, JS | 2 |
| Chen, LT | 1 |
| Yen, CJ | 1 |
| Lee, KD | 1 |
| Su, WP | 1 |
| Lin, PC | 2 |
| Lu, CH | 1 |
| Tsai, HJ | 1 |
| Chao, Y | 1 |
| Villanueva, C | 1 |
| Chaigneau, L | 1 |
| Dufresne, A | 1 |
| Thierry Vuillemin, A | 1 |
| Stein, U | 1 |
| Demarchi, M | 1 |
| Bazan, F | 1 |
| N'guyen, T | 1 |
| Pivot, X | 1 |
| Ferrero, JM | 1 |
| Largillier, R | 1 |
| Michel, C | 1 |
| Amiot, V | 1 |
| Milano, G | 2 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Courdi, A | 1 |
| Figl, A | 1 |
| Follana, P | 1 |
| Barrière, J | 1 |
| Chamorey, E | 1 |
| Nishina, T | 1 |
| Sugimoto, N | 1 |
| Tsuji, Y | 1 |
| Moriwaki, T | 1 |
| Esaki, T | 1 |
| Hamada, C | 1 |
| Tanase, T | 1 |
| Kim, K | 1 |
| Nam, E | 1 |
| Lee, NS | 1 |
| Lee, HR | 2 |
| Lee, JY | 1 |
| Park, SH | 1 |
| Oh, SY | 1 |
| Kim, JH | 1 |
| Song, SY | 1 |
| Park, JO | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Lee, MH | 1 |
| Lee, WY | 1 |
| Chun, H | 1 |
| Park, CH | 1 |
| Park, K | 1 |
| Kang, WK | 1 |
| Douillard, JY | 4 |
| Skillings, JR | 1 |
| Eisenberg, P | 1 |
| Davidson, N | 1 |
| Harper, P | 1 |
| Vincent, MD | 1 |
| Lembersky, BC | 1 |
| Thompson, S | 1 |
| Maniero, A | 1 |
| Benner, SE | 1 |
| Carmichael, J | 1 |
| Popiela, T | 1 |
| Radstone, D | 1 |
| Falk, S | 1 |
| Oza, A | 1 |
| Skovsgaard, T | 1 |
| Munier, S | 1 |
| Martin, C | 1 |
| Rothenberg, ML | 1 |
| Benedetti, JK | 1 |
| Macdonald, JS | 1 |
| Seay, TE | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Yang, TS | 1 |
| Wang, JY | 1 |
| Tang, R | 1 |
| Hsu, KC | 1 |
| Fishman, AD | 1 |
| Wadler, S | 1 |
| Urien, S | 1 |
| Fumoleau, P | 2 |
| Campone, M | 1 |
| Kerbrat, P | 1 |
| Bonneterre, J | 1 |
| Fargeot, P | 1 |
| Deporte-Fety, R | 1 |
| Heslin, MJ | 1 |
| Yan, J | 1 |
| Weiss, H | 1 |
| Shao, L | 1 |
| Owens, J | 1 |
| Lucas, VS | 1 |
| Diasio, RB | 1 |
| Isomoto, H | 1 |
| Tomita, M | 2 |
| Sugimachi, K | 1 |
| Ogawa, M | 1 |
| Yamada, K | 1 |
| Nakagoe, T | 2 |
| Takano, S | 1 |
| Kakegawa, T | 1 |
| DALMAUCIRIA, M | 1 |
| VIETTI, TJ | 1 |
| BERRY, DH | 1 |
| FERNBACH, DJ | 1 |
| LUSHER, J | 1 |
| SUTOW, WW | 1 |
| Ward, S | 1 |
| Kaltenthaler, E | 1 |
| Cowan, J | 1 |
| Brewer, N | 1 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Cats, A | 1 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Nakagawa, F | 1 |
| Fukushima, M | 2 |
| Kitazato, K | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Chua, DT | 1 |
| Kwong, PW | 1 |
| Cheng, AC | 1 |
| Wu, PM | 1 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 1 |
| Wan, KY | 1 |
| Chan, RT | 1 |
| Choy, DD | 1 |
| Gyldenkerne, N | 1 |
| Glimelius, B | 1 |
| Frödin, JE | 1 |
| Kjaer, M | 1 |
| Hansen, F | 2 |
| Keldsen, N | 1 |
| Sandberg, E | 2 |
| Jakobsen, A | 2 |
| Maruyama, S | 1 |
| Maruyama, M | 1 |
| Koide, A | 1 |
| Ohbu, M | 1 |
| Hasegawa, K | 1 |
| Takashima, I | 1 |
| Ebuchi, M | 1 |
| Kono, T | 1 |
| Ebisawa, Y | 1 |
| Tomita, I | 1 |
| Chisato, N | 1 |
| Kamiya, K | 1 |
| Asama, T | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Kohgo, Y | 1 |
| Kasai, S | 1 |
| Wilhelm, L | 1 |
| Kolesar, JM | 1 |
| Rosati, G | 1 |
| Cordio, S | 1 |
| Tucci, A | 1 |
| Blanco, G | 1 |
| Bordonaro, R | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 1 |
| Bennouna, J | 3 |
| Perrier, H | 2 |
| Paillot, B | 1 |
| Priou, F | 1 |
| Jacob, JH | 1 |
| Hebbar, M | 1 |
| Bordenave, S | 1 |
| Seitz, JF | 1 |
| Cvitkovic, F | 1 |
| Dorval, E | 1 |
| Malek, K | 1 |
| Tonelli, D | 1 |
| Goyle, S | 1 |
| Maraveyas, A | 1 |
| Sastre, J | 1 |
| Aranda, E | 1 |
| Abad, A | 1 |
| Gallego, J | 1 |
| Manzano, JL | 1 |
| Gómez, A | 1 |
| Carrato, A | 1 |
| López, E | 1 |
| Díaz-Rubio, E | 2 |
| Munoz, R | 2 |
| Man, S | 2 |
| Shaked, Y | 1 |
| Lee, CR | 1 |
| Wong, J | 1 |
| Francia, G | 1 |
| Kerbel, RS | 2 |
| Saletti, P | 1 |
| Cavalli, F | 1 |
| Chen, WS | 1 |
| Chao, TC | 1 |
| Yang, SH | 1 |
| Tiu, CM | 1 |
| Liu, JH | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Mariani, L | 1 |
| Zilembo, N | 1 |
| Ferrario, E | 1 |
| Lo Vullo, S | 1 |
| Aitini, E | 1 |
| Isa, L | 1 |
| Barone, C | 1 |
| Jacobelli, S | 1 |
| Recaldin, E | 1 |
| Pinotti, G | 1 |
| Iop, A | 1 |
| Delord, JP | 1 |
| Artru, P | 1 |
| Husseini, F | 1 |
| Desseigne, F | 1 |
| François, E | 2 |
| Faroux, R | 1 |
| Smith, D | 1 |
| Piedbois, P | 1 |
| Naman, H | 1 |
| Bugat, R | 1 |
| Vormittag, L | 1 |
| Kornek, GV | 1 |
| Gruhsmann, B | 1 |
| Lenauer, A | 1 |
| Föger, A | 1 |
| Depisch, D | 1 |
| Lang, F | 1 |
| Scheithauer, W | 1 |
| Etienne-Grimaldi, MC | 1 |
| Cardot, JM | 1 |
| Renée, N | 1 |
| Gamelin, E | 1 |
| Château, Y | 1 |
| Tashima, R | 1 |
| Yokoyama, S | 1 |
| Yamashita, Y | 1 |
| Baba, K | 1 |
| Matsuda, M | 1 |
| Di Meglio, G | 1 |
| Fazio, N | 1 |
| Nolè, F | 1 |
| Della Vigna, P | 1 |
| Lorizzo, K | 1 |
| Goldhirsch, A | 1 |
| Farris, A | 1 |
| Passardi, A | 1 |
| Maltoni, R | 1 |
| Milandri, C | 1 |
| Cecconetto, L | 1 |
| Massa, I | 1 |
| Zoli, W | 1 |
| Tesei, A | 1 |
| Fabbri, F | 1 |
| Nanni, O | 1 |
| Amadori, D | 1 |
| Hochster, HS | 1 |
| Luo, W | 1 |
| Popa, EC | 1 |
| Lyman, BT | 1 |
| Mulcahy, M | 1 |
| Beatty, PA | 1 |
| Benson, AB | 1 |
| Geboes, K | 1 |
| Okabayashi, K | 1 |
| Hasegawa, H | 1 |
| Ishii, Y | 1 |
| Endo, T | 1 |
| Ochiai, H | 1 |
| Kubota, T | 1 |
| Kitagawa, Y | 1 |
| Kunitomo, K | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Tamura, T | 1 |
| Yoshikawa, H | 1 |
| Toyosaki, M | 1 |
| Komi, N | 1 |
| Kurebayashi, J | 2 |
| Sonoo, H | 2 |
| Pazdur, R | 3 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Bready, B | 1 |
| Villalon, AH | 1 |
| De Guzman, LM | 1 |
| Samson, MC | 1 |
| Guancia, AA | 1 |
| Fernando, GY | 1 |
| Romana, IB | 1 |
| Matsushita, K | 1 |
| Kuramitsu, Y | 1 |
| Ohiro, Y | 1 |
| Obara, M | 1 |
| Kobayashi, M | 1 |
| Li, YQ | 1 |
| Hosokawa, M | 1 |
| Nukatsuka, M | 1 |
| Fujioka, A | 2 |
| Saito, H | 2 |
| Takeda, S | 2 |
| Unemi, N | 2 |
| Fukumori, H | 1 |
| Kurosumi, M | 1 |
| Dickson, RB | 1 |
| Dickson, NR | 1 |
| Nicholson, BP | 1 |
| Hande, K | 1 |
| Blanke, C | 1 |
| Johnson, D | 1 |
| Cohen, A | 1 |
| Klaassen, U | 1 |
| Borquez, D | 1 |
| Lang, S | 1 |
| Oberhoff, C | 1 |
| Harstrick, A | 1 |
| Seeber, S | 1 |
| Benner, S | 1 |
| Lück, HJ | 1 |
| Scholz, U | 1 |
| Kühnle, H | 1 |
| Dethling, J | 1 |
| Uchida, J | 1 |
| Sato, K | 1 |
| Okabe, H | 1 |
| Nakano, K | 1 |
| Takechi, T | 1 |
| Mani, S | 1 |
| Beck, T | 1 |
| Chevlen, EM | 1 |
| O'Rourke, MA | 1 |
| Weaver, CH | 1 |
| Bell, WN | 2 |
| White, R | 1 |
| McGuirt, C | 1 |
| Levin, J | 2 |
| Hohneker, J | 1 |
| Schilsky, RL | 2 |
| Lokich, J | 1 |
| Feliu, J | 1 |
| López Alvarez, MP | 1 |
| Jaraiz, MA | 1 |
| Constenla, M | 1 |
| Vicent, JM | 1 |
| Belón, J | 1 |
| López Gómez, L | 1 |
| de Castro, J | 1 |
| Dorta, J | 1 |
| González Barón, M | 1 |
| Martín, M | 1 |
| Casado, A | 1 |
| Macias, JA | 1 |
| Garcia-Carbonero, I | 1 |
| Garcia-Saenz, JA | 1 |
| Oruezabal, M | 1 |
| Manrique, I | 1 |
| Aabo, K | 1 |
| Ravaud, A | 1 |
| Schellens, JH | 1 |
| Geoffrois, L | 1 |
| Schöffski, BP | 1 |
| Kroon, K | 1 |
| Wanders, J | 1 |
| Hanauske, AR | 1 |
| Lam, P | 1 |
| Yuen, AP | 1 |
| Ho, CM | 1 |
| Ho, WK | 1 |
| Wei, WI | 1 |
| Ishikura, H | 1 |
| Kondo, K | 1 |
| Miyoshi, T | 1 |
| Kinoshita, H | 1 |
| Takahashi, Y | 1 |
| Fujino, H | 1 |
| Monden, Y | 1 |
| West, WH | 1 |
| Wong, A | 1 |
| Colwell, B | 1 |
| Thirlwell, MP | 1 |
| Ansari, RH | 1 |
| White, RL | 1 |
| Yates, BB | 1 |
| McGuirt, PV | 1 |
| Holen, KD | 1 |
| Saltz, LB | 1 |
| Valero, V | 1 |
| Cristofanilli, M | 1 |
| Frye, DK | 1 |
| Rosales, MM | 1 |
| Croockewit, AJ | 1 |
| de Boer, JE | 1 |
| van Loenhout, JW | 1 |
| Koopmans, PP | 1 |
| Ishikawa, H | 1 |
| Shimizu, T | 1 |
| Hirano, T | 1 |
| Eida, K | 1 |
| Ishii, T | 1 |
| Tobinaga, K | 1 |
| Kotake, Y | 1 |
| Nogawa, T | 1 |
| Fujioka, T | 1 |
| Hasegawa, M | 1 |
| Ishikura, K | 1 |
| Nomura, K | 1 |
| Okamoto, T | 1 |
| Tanji, S | 1 |
| Koike, H | 1 |
| Kubo, T | 1 |
| Aoki, Y | 1 |
| Tabuse, Y | 1 |
| Tanimura, H | 1 |
| Katsumi, M | 1 |
| Asae, M | 1 |
| Ichimiya, G | 1 |
| Imai, T | 1 |
| Ooshima, K | 1 |
| Kakihara, M | 1 |
| Kashitani, M | 1 |
| Iaremenko, KV | 1 |
| Frid, IA | 1 |
| Fidler, IJ | 1 |
| Lieber, S | 1 |
| Elbe, B | 1 |
| Nowak, C | 1 |
| Arnold, W | 1 |
| Bender, E | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Mardakhiashvili, ShI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies[NCT01607957] | Phase 3 | 800 participants (Actual) | Interventional | 2012-06-17 | Completed | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer[NCT00004860] | Phase 2 | 0 participants | Interventional | 2000-10-09 | Completed | ||
| A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes[NCT03121313] | Phase 2 | 68 participants (Anticipated) | Interventional | 2015-02-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 7.1 |
| Placebo | 5.3 |
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 2.0 |
| Placebo | 1.7 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs. (NCT01607957)
Timeframe: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | Any treatment-related AE | Any ≥Grade 3 AE | Any treatment-related ≥Grade 3 AE | Any serious AE (SAE) | Any AE resulting in discontinuation | Any AE with outcome of death | |
| Placebo | 93.2 | 54.7 | 51.7 | 9.8 | 33.6 | 13.6 | 11.3 |
| TAS-102 | 98.3 | 85.7 | 69.4 | 49.0 | 29.6 | 10.3 | 3.2 |
19 reviews available for uracil and Neoplasm Metastasis
| Article | Year |
|---|---|
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disea | 2020 |
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2020 |
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Colorectal Neoplasms; Double-Blind Me | 2020 |
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla | 2018 |
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Co | 2018 |
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resist | 2019 |
TAS-102 for the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com | 2015 |
Current and advancing treatments for metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2016 |
A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Huma | 2016 |
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 2017 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; | 2001 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2003 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
Metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2006 |
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclophosphamide; Disease Models, Animal; Drug Com | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com | 2007 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2002 |
55 trials available for uracil and Neoplasm Metastasis
| Article | Year |
|---|---|
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2019 |
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Protocols; Colorectal Neoplasm | 2020 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin | 2020 |
Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2014 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
TAS-102 for metastatic refractory colorectal cancer.
Topics: Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Neoplasm Metas | 2015 |
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorec | 2015 |
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; | 2016 |
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Topics: Aged; Colon; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; | 2017 |
Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.
Topics: Adult; Aged; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metast | 2017 |
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2010 |
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leuc | 2010 |
A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doceta | 2010 |
Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2011 |
A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female | 2011 |
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female | 2012 |
Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2003 |
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Female; Humans; K | 2003 |
Pre- and post-operative adjuvant chemotherapy in colorectal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Mid | 2003 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2005 |
Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2005 |
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2006 |
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Dru | 2007 |
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2007 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1997 |
Phase II study of UFT plus leucovorin in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Combinations; | 1997 |
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Therapy, Combina | 1999 |
Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 1999 |
UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adminis | 1999 |
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2000 |
Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasm Me | 2000 |
Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Hematopoietic Stem Ce | 2000 |
Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2001 |
Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; He | 2001 |
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2002 |
[Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neo | 1989 |
40 other studies available for uracil and Neoplasm Metastasis
| Article | Year |
|---|---|
A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Human | 2021 |
Sequencing beyond the second-line setting in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2019 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2020 |
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Agents; California; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; E | 2017 |
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects a | 2020 |
Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; | 2019 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middl | 2015 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2016 |
In brief: trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug | 2016 |
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Combi | 2017 |
[Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female | 2009 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
URACIL MUSTARY THERAPY IN METASTATIC WILMS'S TUMOR.
Topics: Anemia; Child; Drug Therapy; Leukopenia; Nausea; Neoplasm Metastasis; Nitrogen Mustard Compounds; Th | 1964 |
Oral tegafur-uracil plus leucovorin in metastatic colorectal cancer: clinical insights. Proceedings of a roundtable expert meeting. October 2002, Nice, France.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Leucovorin; | 2003 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials | 2005 |
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2006 |
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2007 |
[A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; L | 2007 |
Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2007 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
[Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Humans; Ly | 1995 |
Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; Basidiomycota; Cell Survival; Drug Combinations; Female; Killer Cells, Natu | 1998 |
Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; | 1997 |
Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.
Topics: Amputation, Surgical; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinom | 2000 |
Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Ne | 2001 |
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1991 |
[Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Screening Assay | 1990 |
[Metastasis of experimental tumors and the functional activity of the hypophysis-adrenal system].
Topics: Adrenocorticotropic Hormone; Anesthesia, General; Animals; Antineoplastic Agents; Corticosterone; Et | 1973 |
Quantitative analysis of the mechanism of glucocorticoid enhancement of experimental metastasis.
Topics: Animals; Cell Transformation, Neoplastic; Cells, Cultured; Glucocorticoids; Iodine Isotopes; Lung; L | 1972 |
[Influence of pretreatment with cyclophosphamide, ribo-azauracil and mercaleukin on experimental metastases in a syngeneic tumour-host-system: II. Chemically induced sarcomas of mouse and rat].
Topics: Animals; Benzopyrenes; Cyclophosphamide; Male; Mercaptopurine; Mice; Mice, Inbred CBA; Neoplasm Meta | 1973 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |
[On the experimental prevention of recurrence and metastaais of malignant tumor with methacil and endoxan].
Topics: Animals; Cyclophosphamide; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rats; Sarcoma, Experimen | 1967 |